» Articles » PMID: 39816468

Immunomodulatory and Biological Properties of Helminth-derived Small Molecules: Potential Applications in Diagnostics and Therapeutics

Overview
Journal Front Parasitol
Date 2025 Jan 16
PMID 39816468
Authors
Affiliations
Soon will be listed here.
Abstract

Parasitic helminths secrete and excrete a vast array of molecules known to help skew or suppress the host's immune response, thereby establishing a niche for sustained parasite maintenance. Indeed, the immunomodulatory potency of helminths is attributed mainly to excretory/secretory products (ESPs). The ESPs of helminths and the identified small molecules (SM) are reported to have diverse biological and pharmacological properties. The available literature reports only limited metabolites, and the identity of many metabolites remains unknown due to limitations in the identification protocols and helminth-specific compound libraries. Many metabolites are known to be involved in host-parasite interactions and pathogenicity. For example, fatty acids (e.g., stearic acid) detected in the infective stages of helminths are known to have a role in host interaction through facilitating successful penetration and migration inside the host. Moreover, excreted/secreted SM detected in helminth species are found to possess various biological properties, including anti-inflammatory activities, suggesting their potential in developing immunomodulatory drugs. For example, helminths-derived somatic tissue extracts and whole crude ESPs showed anti-inflammatory properties by inhibiting the secretion of proinflammatory cytokines from human peripheral blood mononuclear cells and suppressing the pathology in chemically-induced experimental mice model of colitis. Unlike bigger molecules like proteins, SM are ideal candidates for drug development since they are small structures, malleable, and lack immunogenicity. Future studies should strive toward identifying unknown SM and isolating the under-explored niche of helminth metabolites using the latest metabolomics technologies and associated software, which hold potential keys for finding new diagnostics and novel therapeutics.

Citing Articles

Cichlid fishes are promising underutilized models to investigate helminth-host-microbiome interactions.

Vanhove M, Koblmuller S, Fernandes J, Hahn C, Plusquin M, Kmentova N Front Immunol. 2025; 16:1527184.

PMID: 40018030 PMC: 11864961. DOI: 10.3389/fimmu.2025.1527184.


Chronic small intestinal helminth infection perturbs bile acid homeostasis and disrupts bile acid signaling in the murine small intestine.

Lane J, Brosschot T, Gatti D, Gauthier C, Lawrence K, Pluzhnikova V Front Parasitol. 2025; 2():1214136.

PMID: 39816838 PMC: 11731828. DOI: 10.3389/fpara.2023.1214136.


Immunomodulators secreted from parasitic helminths act on pattern recognition receptors.

Tsubokawa D Front Parasitol. 2025; 1():1091596.

PMID: 39816467 PMC: 11731691. DOI: 10.3389/fpara.2022.1091596.


Helminth-derived biomolecules as potential therapeutics against ulcerative colitis.

Chakraborty A, Bayry J, Mukherjee S Immunotherapy. 2024; 16(10):635-640.

PMID: 38888436 PMC: 11404699. DOI: 10.1080/1750743X.2024.2360382.

References
1.
Liaudet L, Mabley J, Soriano F, Pacher P, Marton A, Hasko G . Inosine reduces systemic inflammation and improves survival in septic shock induced by cecal ligation and puncture. Am J Respir Crit Care Med. 2001; 164(7):1213-20. DOI: 10.1164/ajrccm.164.7.2101013. View

2.
Becker A, Willenberg I, Springer A, Schebb N, Steinberg P, Strube C . Fatty acid composition of free-living and parasitic stages of the bovine lungworm Dictyocaulus viviparus. Mol Biochem Parasitol. 2017; 216:39-44. DOI: 10.1016/j.molbiopara.2017.06.008. View

3.
Giera M, Kaisar M, Derks R, Steenvoorden E, Kruize Y, Hokke C . The Schistosoma mansoni lipidome: Leads for immunomodulation. Anal Chim Acta. 2018; 1037:107-118. DOI: 10.1016/j.aca.2017.11.058. View

4.
Ruddigkeit L, van Deursen R, Blum L, Reymond J . Enumeration of 166 billion organic small molecules in the chemical universe database GDB-17. J Chem Inf Model. 2012; 52(11):2864-75. DOI: 10.1021/ci300415d. View

5.
Huang X, Zeng L, Chen F, Zhu J, Zhu M . Trichuris suis ova therapy in inflammatory bowel disease: A meta-analysis. Medicine (Baltimore). 2018; 97(34):e12087. PMC: 6113037. DOI: 10.1097/MD.0000000000012087. View